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The above case report (pp. 199–200) focuses once again on the
skin as a prominent and visible site of presentation of a systemic
B-cell lymphoma. This is certainly worthy of note, and pushes
us to face critically the issue of B-cell non-Hodgkin’s lymph-
omas (NHLs) and the skin.
First, primary cutaneous B-cell lymphomas (CBCLs) are an
established reality, and must be clearly separated from second-
ary CBCLs. In fact, the former do not require aggressive treat-
ment and their prognosis is overall excellent.
 
1,2
 
 This is different
from the latter, which are the expression of dissemination from
a primarily extracutaneous site. It remains to be clarified
whether concurrent CBCLs, i.e. those simultaneously present-
ing in the skin and also lymphoid organs and/or other extran-
odal sites (e.g. mucosa-associated lymphoid tissue, MALT) do
behave different from secondary CBCLs. In our experience, the
comparison of primary, concurrent and secondary CBCLs,
although biased by the different size of the studied groups of
patients, seems to indicate that concurrent CBCLs have clinico-
pathologic, immunologic and prognostic features much closer
to those of primary CBCLs.
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The second point to be faced is how frequent is the occur-
rence of primary CBCLs. According to the literature and general
international experience, primary CBCLs are less frequent than
CTCLs, with figures varying greatly between European
 
2,4
 
 and
American studies.
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 However, according to the results of a
population-based study carried out in the Florence district
(198
 
6
 
–1995),
 
6
 
 primary CBCLs account for 66.6% of the total
number of primary cutaneous lymphoma patients (
 
n
 
 = 132; the
second most common extranodal NHLs, which account for
more than one-third of the total number of NHLs), with a crude
incidence rate of 0.7 per 100 000 inhabitants per year (standard-
ized incidence rate = 0.5), which is clearly higher than that of
CTCLs (crude incidence rate = 0.3, standardized incidence
rate = 0.2). These findings can certainly be influenced by the
systematic application of immunohistochemical (light chain
monoclonal restriction of surface and/or cytoplasmic immuno-
globulins) and molecular criteria (heavy chain monoclonal
rearrangement) for the diagnosis of primary CBCLs, with the
consequent higher likelihood of detecting very early cases. In
this regard, a recent British study seems to confirm the more
frequent and confident diagnosis of primary CBCLs as one of
the major causes for the clearly increasing incidence of extran-
odal NHLs.
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Another very interesting issue, for both scientific and pract-
ical reasons, concerns the clinical relevance, the reproducibility
and, more important, the prognostic significance of the categor-
ization of primary CBCLs into specific subgroups. According
to the European Organization for Research and Treatment of
Cancer (EORTC) classification of primary cutaneous lympho-
mas,
 
2
 
 primary CBCLs are divided into three subgroups. Two of
them, the so-called follicle centre cell lymphoma (FCCL) and
the immunocytoma/marginal zone lymphoma (MZL) due
to their histological similarities with their purported nodal
counterparts, account for more than 90% of all patients with a
definite diagnosis of primary CBCL. They have a mostly regional
extension and an indolent clinical behaviour, with good
response to local radiotherapy, low tendency to extracutaneous
spread, and excellent prognosis.
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 The main differential
features are as follows. FCCLs are mainly located on the trunk
and on the head and neck. Histologically, they are composed of
cells reminiscent of the morphologies of FCCs, usually a mixture
of small and large cleaved cells (putative centrocytes) and large
cells with prominent nuclei and nucleoli (putative centroblasts
and immunoblasts).
 
2
 
 Additional criteria, especially in cases
with a follicular growth pattern, are a reduced mantle zone, a
reduced proliferation rate and the absence of tingible body
macrophages in the follicle centre compared to reactive folli-
cles, and the bcl–6+, CD10+ phenotype of neoplastic cells.
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Conversely, MZLs are usually located on arms or legs. Histolo-
gically, the findings of lymphoplasmacytoid/plasmacytoid cells
located at the periphery of the nodular infiltrates
 
2,9,11
 
 and the
‘colonization’ of reactive lymphoid follicles by bcl6–, CD5–,
CD10– neoplastic cells
 
9,11
 
 are considered the clues to diagnosis.
In our experience on a large series of 274 patients, this strict
type of categorization is clinically and histologically difficult to
reproduce. In fact, in the 245 patients of our series with an indo-
lent course (89.4%), we did not observe a significant variation
in the sites of presentation (trunk and head and neck vs limbs)
in relation to different histology, although it was very clear that
the regional extension of the disease is the rule (90.6% in our
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series). Moreover, the above distinctive features of FCCLs and
MZLs are very hard to find in early lesions, characterized by
small clusters of centrocyte-like neoplastic B cells with a CD5–,
CD10–, bcl2–, bcl6+/– phenotype and an overwhelming pre-
dominance of reactive T cells. Even in more developed lesions,
different histologic pictures (FCCL-like, with CD10 antigen
expression much less useful that bcl6 protein expression in our
hands, and MZL-like) are often found in different lesions of the
same patient (so-called ‘discordant’ picture) or even in different
areas of the same lesion (so-called ‘composite’ picture). The
above features plus others, including polymorphism of the
neoplastic infiltrate, with cells showing a fluent transition of
sizes and shapes, and variable extent of reactive T- and B-cell
infiltrate according to the size, age and growth rate of skin
lesions; uniformly negative bcl2 gene rearrangement;
 
12–14
 
 typical,
although not frequent, finding of lymphoepithelial lesions,
 
1
 
induced us to suggest the holistic interpretation of indolent
primary CBCLs as skin-associated lymphoid tissue (SALT)-
related B-cell lymphomas
 
15–17
 
 on the basis of the close similarities
with MALT lymphomas. Relative problems of categorization
and subtle differences of interpretation apart, it is a fact that
indolent primary CBCLs are common (nearly 90% of all
primary CBCL cases), show a very good response to non-
aggressive treatment (local radiotherapy), and – despite rel-
atively frequent relapses (24.7% in our series, with a median
disease-free interval of 42 months) – have an excellent prognosis
(98.5% 5-year survival). One very interesting feature is the lack
of correlation between histologic progression to diffuse large
cell infiltrate and either the clinical course or the prognosis of
the disease, which is excellent (different from nodal B-cell
NHLs).
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 A third, much smaller, subgroup with intermediate
prognosis (the so-called large B-cell lymphoma of the leg)
 
18
 
 is
identified in the EORTC classification.
 
2
 
 It is characterized by
rapid growth of skin lesions (plaques, nodules and/or tumours),
 
de novo
 
 diffuse large cell infiltrate histology (diffuse large B-cell
lymphoma, DLBCL), high proliferation rate, strong bcl2 pro-
tein expression, predilection for the elderly (> 70 years of age)
and selected skin sites (lower legs), and much less favourable
prognosis (58% 5-year survival). The results of a recently
published European multicentre study on a large group of
patients
 
19
 
 indicate that large ‘round’ cell (i.e. centroblast- and
immunoblast-like) histology and old age (> 70 years) are the
most potent factors significantly associated with a more aggres-
sive behaviour and worse prognosis compared to indolent
primary CBCLs. Our experience with 29 patients with DLBCL
(10.6% in our series of 274 patients) is in line with all the above
features (old age, median 79 years, at presentation; higher
relapse rate, 41.3% vs. 24.7% in the indolent group; shorter
disease-free interval, 15 vs 42 months; relative predilection for
the lower limbs, 17/29 patients) except for prognosis. In fact, the
5-year survival of the DLBCL group (95.1%) is not significantly
different from that of the indolent group (98.5%). In addition,
only one of the three patients who died of disease had lesions of
the lower limbs. Our experience in this regard is shared with
other groups.
 
14,20
 
The slight differences depicted above will find, it is hoped, a
reasonable explanation by further clinico-pathologic, epidemi-
ologic and molecular studies. However, there is no doubt that
primary CBCLs are a distinct entity, to be clearly separated from
secondary CBCLs, and that the EORTC classification is cur-
rently the most careful and useful to categorize them.
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